213 related articles for article (PubMed ID: 30462260)
1. Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria.
Steffen R; Jiang ZD; Gracias Garcia ML; Araujo P; Stiess M; Nacak T; Greinwald R; DuPont HL
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30462260
[TBL] [Abstract][Full Text] [Related]
2. Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.
DuPont HL; Petersen A; Zhao J; Mundt A; Jiang ZD; Miller S; Flores J; Shringarpure R; Moro L; Bagin RG; Ballard ED; Totoritis MC
J Travel Med; 2014; 21(6):369-76. PubMed ID: 25345982
[TBL] [Abstract][Full Text] [Related]
3. Rifamycin SV MMX for the treatment of traveler's diarrhea.
Lin SW; Lin CJ; Yang JC
Expert Opin Pharmacother; 2017 Aug; 18(12):1269-1277. PubMed ID: 28697313
[TBL] [Abstract][Full Text] [Related]
4. Rifamycin SV MMX
Hoy SM
Clin Drug Investig; 2019 Jul; 39(7):691-697. PubMed ID: 31172447
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
[TBL] [Abstract][Full Text] [Related]
6. Development of a new travellers' diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy.
DuPont HL; Almenoff JS; Jamindar MS; Bortey E; Steffen R
J Travel Med; 2023 Oct; 30(6):. PubMed ID: 37052453
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Farrell DJ; Putnam SD; Biedenbach DJ; Moro L; Bozzella R; Celasco G; Jones RN
Antimicrob Agents Chemother; 2011 Mar; 55(3):992-6. PubMed ID: 21149623
[TBL] [Abstract][Full Text] [Related]
8. Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.
Steffen R; DuPont HL
J Travel Med; 2019 May; 26(3):. PubMed ID: 30848824
[No Abstract] [Full Text] [Related]
9. Travel to Asia and traveller's diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrum β-lactamase-producing Enterobacteriaceae-a prospective cohort study.
Reuland EA; Sonder GJ; Stolte I; Al Naiemi N; Koek A; Linde GB; van de Laar TJ; Vandenbroucke-Grauls CM; van Dam AP
Clin Microbiol Infect; 2016 Aug; 22(8):731.e1-7. PubMed ID: 27223840
[TBL] [Abstract][Full Text] [Related]
10. Ecological effects of short-term ciprofloxacin treatment of travellers' diarrhoea.
Wiström J; Gentry LO; Palmgren AC; Price M; Nord CE; Ljungh A; Norrby SR
J Antimicrob Chemother; 1992 Nov; 30(5):693-706. PubMed ID: 1493985
[TBL] [Abstract][Full Text] [Related]
11. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
12. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea.
Layer P; Andresen V
Aliment Pharmacol Ther; 2010 Jun; 31(11):1155-64. PubMed ID: 20331580
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum beta-lactamase-producing strains among diarrhoeagenic Escherichia coli-prospective traveller study with literature review.
Kantele A; Lääveri T
J Travel Med; 2022 Jan; 29(1):. PubMed ID: 33834207
[TBL] [Abstract][Full Text] [Related]
14. Despite antibiotic treatment of travellers' diarrhoea, pathogens are found in stools from half of travellers at return.
Lääveri T; Vilkman K; Pakkanen S; Kirveskari J; Kantele A
Travel Med Infect Dis; 2018; 23():49-55. PubMed ID: 29702254
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008.
Ouyang-Latimer J; Jafri S; VanTassel A; Jiang ZD; Gurleen K; Rodriguez S; Nandy RK; Ramamurthy T; Chatterjee S; McKenzie R; Steffen R; DuPont HL
Antimicrob Agents Chemother; 2011 Feb; 55(2):874-8. PubMed ID: 21115800
[TBL] [Abstract][Full Text] [Related]
16. Travelers' Diarrhea-Associated Enterotoxigenic Escherichia coli gyrA Mutants and Quinolone Antibiotic Affinity: A Molecular Dynamics Simulation and Residue Interaction Network Analysis.
Mehla K; Ramana J
OMICS; 2016 Nov; 20(11):635-644. PubMed ID: 27753544
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.
DuPont HL; Jiang ZD; Ericsson CD; Adachi JA; Mathewson JJ; DuPont MW; Palazzini E; Riopel LM; Ashley D; Martinez-Sandoval F
Clin Infect Dis; 2001 Dec; 33(11):1807-15. PubMed ID: 11692292
[TBL] [Abstract][Full Text] [Related]
18. Resistance Pattern and Molecular Characterization of Enterotoxigenic Escherichia coli (ETEC) Strains Isolated in Bangladesh.
Begum YA; Talukder KA; Azmi IJ; Shahnaij M; Sheikh A; Sharmin S; Svennerholm AM; Qadri F
PLoS One; 2016; 11(7):e0157415. PubMed ID: 27428376
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
20. Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic
Guiral E; Gonçalves Quiles M; Muñoz L; Moreno-Morales J; Alejo-Cancho I; Salvador P; Alvarez-Martinez MJ; Marco F; Vila J
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
